Sanjay Chandru Keswani, Chief Medical Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), filed a Form 4 on September 15, 2026, disclosing changes in beneficial ownership of common stock stemming from the vesting of performance restricted stock units on September 11, 2026.

Key Highlights

  • PRSU vesting: 3,914 shares of common stock were acquired at $0 on September 11, 2026, following certification of a performance metric achievement tied to previously granted performance restricted stock units.
  • Tax withholding: 2,112 shares were withheld by Neurocrine Biosciences to satisfy tax withholding requirements on the PRSU vesting, at a price of $156.22 per share.
  • No open-market sale: According to the filing, "No shares were sold."
  • Resulting ownership: Following both transactions, Keswani directly beneficially owned 3,281 shares of common stock.
  • Reporting person role: Keswani is identified in the filing as Chief Medical Officer of Neurocrine Biosciences Inc.

PRSU Certification and Share Withholding at Neurocrine Biosciences

According to the Form 4 filed with the SEC, Sanjay Chandru Keswani, Chief Medical Officer of Neurocrine Biosciences Inc., reported two transactions in the company's common stock on September 11, 2026. The first was an acquisition of 3,914 shares at a price of $0, described in the filing as resulting from performance restricted stock units that were previously granted and that "vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026."

The second transaction was a disposition of 2,112 shares at $156.22 per share, coded "F" in the filing. The filing explains that these shares were "withheld by Neurocrine Biosciences, Inc. (the 'Company' or 'Issuer') to satisfy tax withholding requirements on vesting of PRSUs." The filing explicitly states that no shares were sold in connection with this withholding. Prior to the acquisition, the filing shows Keswani held 1,479 shares directly, rising to 5,393 after the PRSU vesting, and then falling to 3,281 after the tax-related withholding.

The Form 4 was signed by Darin Lippoldt as Attorney-in-Fact on September 15, 2026, and filed on the same date. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing discloses a PRSU vesting event for Neurocrine Biosciences' Chief Medical Officer, resulting in the acquisition of 3,914 shares and the withholding of 2,112 shares for tax purposes, leaving the officer with direct beneficial ownership of 3,281 shares.